Social Responsibility

Data-sharing, discovery and insights

Data-driven insights are vital to advancing scientific innovation and improving health outcomes. Patients and providers are at the center of our mission to make genetic testing and data-driven medical information more widely available. Myriad Genetics maintains close relationships with healthcare providers and health systems, academic centers, government agencies, and other collaborators to maintain the integrity and security of shared data for use in clinical care and scientific research.

• Beginning in Spring 2023, we will share clinically impactful hereditary cancer and prenatal data submissions with the ClinVar public database. ClinVar is operated by the National Center for Biotechnology Information (NCBI), part of the National Institutes of Health (NIH), to help aggregate information about genomic variation and its relationship to public health. We will continue to submit prenatal germline variants to ClinVar, consistent with our already established practice. For our oncology products, we will immediately focus on sharing more recently identified or reclassified pathogenic/likely pathogenic germline sequencing variants, as they are the most clinically impactful.
• With our new suite of Precise Oncology Solutions, Myriad launched the Precise Treatment Registry available to all healthcare providers to help advance equitable patient care and accelerate the pace of precision cancer research. It combines targeted tumor, germline and homologous recombination deficiency (HRD) genetic data, allowing physicians to access clinical insights on key patient populations. The registry enables clinicians to explore hypotheses in real time by analyzing diverse de-identified patient data involving ancestry, geography, cancer diagnosis, treatment outcomes and more. Open to all healthcare providers who register, the Precise™ Treatment Registry is powered by DNAnexus’ secure cloud bioinformatics platform for scientific data analysis, collaboration and discovery.
• We contribute hereditary cancer data to the California and Georgia SEER registries, funded by the National Cancer Institute. The registries collect and publish cancer incidence, prevalence, and survival data.
• We share our expertise and classification advancements through more than 1,000 scientific publications to date, including specific variant classifications in addition to internal approaches to variant classifications and reclassifications. These studies are conducted in partnership with leading industry collaborators and are regularly published in peer-reviewed journals such as the Journal of the American Medical Association, Psychiatry Research, Annals of Oncology, Cancer Genetics, JCO Precision Oncology and others.
• Myriad Genetics has a lifetime commitment to provide patients who have received hereditary cancer test results with timely, up-to-date information on their gene variants. Through our work, we are learning more about genetics every day – some of which has a material impact on the millions of patients who have undergone our testing in the past.
• We share data and classifications relevant to specific medical requests. We also share data and research at major medical association meetings and industry conferences.

We value the trust patients and healthcare providers have placed in us. We continue to identify ways to further leverage our datasets as part of our mission to improve health and well-being for all, and enable healthcare providers to better detect, treat and prevent disease.